A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

MLA

O’Brien, Susan M., et al. “A Phase 2 Study of Idelalisib plus Rituximab in Treatment-Naïve Older Patients with Chronic Lymphocytic Leukemia.” Blood, vol. 126, no. 25, Dec. 2015, pp. 2686–94. EBSCOhost, https://doi.org/10.1182/blood-2015-03-630947.

APA

O’Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., Keating, M., Mitra, S., Holes, L., Yu, A. S., Johnson, D. M., Miller, L. L., Yeonhee Kim, Dansey, R. D., Dubowy, R. L., & Coutre, S. E. (2015). A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood, 126(25), 2686–2694. https://doi.org/10.1182/blood-2015-03-630947

Chicago

O’Brien, Susan M., Nicole Lamanna, Thomas J. Kipps, Ian Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael Keating, et al. 2015. “A Phase 2 Study of Idelalisib plus Rituximab in Treatment-Naïve Older Patients with Chronic Lymphocytic Leukemia.” Blood 126 (25): 2686–94. doi:10.1182/blood-2015-03-630947.